Medmix Ltd
SIX:MEDX

Watchlist Manager
Medmix Ltd Logo
Medmix Ltd
SIX:MEDX
Watchlist
Price: 8.93 CHF -0.67% Market Closed
Market Cap: CHf368.5m

Wall St Price Targets

MEDX Price Targets Summary
Medmix Ltd

Wall Street analysts forecast MEDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEDX is 15.27 CHF with a low forecast of 13.64 CHF and a high forecast of 16.8 CHF.

Lowest Forecast
Price Target
13.64 CHF
53% Upside
Average Forecast
Price Target
15.27 CHF
71% Upside
Highest Forecast
Price Target
16.8 CHF
88% Upside
Medmix Ltd Competitors:
Price Targets
BC
Brunello Cucinelli SpA
27% Upside
9688
Zai Lab Ltd
4% Upside
FDMT
4D Molecular Therapeutics Inc
102% Upside
PAT
Panthera Resources PLC
285% Upside
CBAN
Colony Bankcorp Inc
16% Upside

Revenue
Forecast

1% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
1% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 6 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 8 years is 5%.

Gross Profit
Forecast

0% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
0% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 6 years, the compound annual growth rate for Gross Profit has been 0%. The projected CAGR for the next 3 years is 5%.

Operating Income
Forecast

-10% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss
-10% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Over the last 6 years, the compound annual growth rate for Operating Income has been -10%. The projected CAGR for the next 8 years is 11%.

Pre-Tax Income
Forecast

-19% / Year
Past Growth
50% / Year
Estimated Growth
Estimates Accuracy
-55%
Average Miss
-19% / Year
Past Growth
50% / Year
Estimated Growth
Estimates Accuracy
-55%
Average Miss

Over the last 6 years, the compound annual growth rate for Pre-Tax Income has been -19%. The projected CAGR for the next 3 years is 50%.

Net Income
Forecast

-20% / Year
Past Growth
54% / Year
Estimated Growth
Estimates Accuracy
-63%
Average Miss
-20% / Year
Past Growth
54% / Year
Estimated Growth
Estimates Accuracy
-63%
Average Miss

Over the last 6 years, the compound annual growth rate for Net Income has been -20%. The projected CAGR for the next 3 years is 54%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is MEDX's stock price target?
Price Target
15.27 CHF

According to Wall Street analysts, the average 1-year price target for MEDX is 15.27 CHF with a low forecast of 13.64 CHF and a high forecast of 16.8 CHF.

What is the Revenue forecast for Medmix Ltd?
Projected CAGR
5%

Over the last 6 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 8 years is 5%.

What is the Gross Profit forecast for Medmix Ltd?
Projected CAGR
5%

Over the last 6 years, the compound annual growth rate for Gross Profit has been 0%. The projected CAGR for the next 3 years is 5%.

What is the Operating Income forecast for Medmix Ltd?
Projected CAGR
11%

Over the last 6 years, the compound annual growth rate for Operating Income has been -10%. The projected CAGR for the next 8 years is 11%.

What is the Pre-Tax Income forecast for Medmix Ltd?
Projected CAGR
50%

Over the last 6 years, the compound annual growth rate for Pre-Tax Income has been -19%. The projected CAGR for the next 3 years is 50%.

What is the Net Income forecast for Medmix Ltd?
Projected CAGR
54%

Over the last 6 years, the compound annual growth rate for Net Income has been -20%. The projected CAGR for the next 3 years is 54%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett